DNLI
Price
$16.50
Change
+$1.06 (+6.87%)
Updated
May 1, 2:18 PM EST
One day until earnings call
RGNX
Price
$16.20
Change
+$0.85 (+5.54%)
Updated
May 1, 6:59 PM EST
Earnings call today
Ad is loading...

DNLI vs RGNX ᐉ Comparison: Which is Better to Invest?

Header iconDNLI vs RGNX Comparison
Open Charts DNLI vs RGNXBanner chart's image
Denali Therapeutics
Price$16.50
Change+$1.06 (+6.87%)
Volume$1.42K
CapitalizationN/A
REGENXBIO
Price$16.20
Change+$0.85 (+5.54%)
Volume$259.15K
CapitalizationN/A
View a ticker or compare two or three
DNLI vs RGNX Comparison Chart

Loading...

DNLIDaily Signal changed days agoGain/Loss if shorted
 
Show more...
RGNXDaily Signal changed days agoGain/Loss if shorted
 
Show more...
VS
DNLI vs. RGNX commentary
May 01, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is DNLI is a Hold and RGNX is a Hold.

COMPARISON
Comparison
May 01, 2024
Stock price -- (DNLI: $15.44 vs. RGNX: $15.35)
Brand notoriety: DNLI and RGNX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: DNLI: 78% vs. RGNX: 52%
Market capitalization -- DNLI: $2.2B vs. RGNX: $752.81M
DNLI [@Biotechnology] is valued at $2.2B. RGNX’s [@Biotechnology] market capitalization is $752.81M. The market cap for tickers in the [@Biotechnology] industry ranges from $566.59B to $0. The average market capitalization across the [@Biotechnology] industry is $2.58B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

DNLI’s FA Score shows that 0 FA rating(s) are green whileRGNX’s FA Score has 1 green FA rating(s).

  • DNLI’s FA Score: 0 green, 5 red.
  • RGNX’s FA Score: 1 green, 4 red.
According to our system of comparison, RGNX is a better buy in the long-term than DNLI.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

DNLI’s TA Score shows that 4 TA indicator(s) are bullish while RGNX’s TA Score has 5 bullish TA indicator(s).

  • DNLI’s TA Score: 4 bullish, 5 bearish.
  • RGNX’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, RGNX is a better buy in the short-term than DNLI.

Price Growth

DNLI (@Biotechnology) experienced а -4.16% price change this week, while RGNX (@Biotechnology) price change was -3.46% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +3.37%. For the same industry, the average monthly price growth was -4.20%, and the average quarterly price growth was +1241.07%.

Reported Earning Dates

DNLI is expected to report earnings on Aug 06, 2024.

RGNX is expected to report earnings on Aug 07, 2024.

Industries' Descriptions

@Biotechnology (+3.37% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
A.I.dvisor published
a Summary for DNLI with price predictions.
OPEN
A.I.dvisor published
a Summary for RGNX with price predictions.
OPEN
FUNDAMENTALS
Fundamentals
DNLI($2.2B) has a higher market cap than RGNX($753M). RGNX YTD gains are higher at: -14.485 vs. DNLI (-28.052).
DNLIRGNXDNLI / RGNX
Capitalization2.2B753M292%
EBITDAN/AN/A-
Gain YTD-28.052-14.485194%
P/E RatioN/AN/A-
RevenueN/AN/A-
Total CashN/AN/A-
Total DebtN/AN/A-
FUNDAMENTALS RATINGS
DNLI vs RGNX: Fundamental Ratings
DNLI
RGNX
OUTLOOK RATING
1..100
5255
VALUATION
overvalued / fair valued / undervalued
1..100
82
Overvalued
78
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9097
PRICE GROWTH RATING
1..100
8558
P/E GROWTH RATING
1..100
9729
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

RGNX's Valuation (78) in the Biotechnology industry is in the same range as DNLI (82). This means that RGNX’s stock grew similarly to DNLI’s over the last 12 months.

RGNX's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as DNLI (100). This means that RGNX’s stock grew similarly to DNLI’s over the last 12 months.

DNLI's SMR Rating (90) in the Biotechnology industry is in the same range as RGNX (97). This means that DNLI’s stock grew similarly to RGNX’s over the last 12 months.

RGNX's Price Growth Rating (58) in the Biotechnology industry is in the same range as DNLI (85). This means that RGNX’s stock grew similarly to DNLI’s over the last 12 months.

RGNX's P/E Growth Rating (29) in the Biotechnology industry is significantly better than the same rating for DNLI (97). This means that RGNX’s stock grew significantly faster than DNLI’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
DNLIRGNX
RSI
ODDS (%)
Bullish Trend 2 days ago
82%
Bullish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
79%
Bullish Trend 2 days ago
80%
Momentum
ODDS (%)
Bearish Trend 2 days ago
85%
N/A
MACD
ODDS (%)
N/A
N/A
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
82%
Bearish Trend 2 days ago
83%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
84%
Bearish Trend 2 days ago
84%
Advances
ODDS (%)
Bullish Trend 3 days ago
79%
Bullish Trend 6 days ago
74%
Declines
ODDS (%)
Bearish Trend 7 days ago
80%
Bearish Trend 2 days ago
83%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
78%
Bullish Trend 2 days ago
77%
Aroon
ODDS (%)
Bearish Trend 2 days ago
82%
Bearish Trend 2 days ago
83%
View a ticker or compare two or three
Ad is loading...
DNLIDaily Signal changed days agoGain/Loss if shorted
 
Show more...
RGNXDaily Signal changed days agoGain/Loss if shorted
 
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
FSPSX48.38-0.55
-1.12%
Fidelity International Index
PIIDX14.00-0.20
-1.41%
Principal International I R-6
MGORX32.17-0.63
-1.92%
Morgan Stanley Inst Global Opp IR
FIQEX65.29-1.42
-2.13%
Fidelity Advisor Canada Z
MSPTX9.54-0.28
-2.85%
Morgan Stanley Inst Global Insgt C

DNLI and

Correlation & Price change

A.I.dvisor indicates that over the last year, DNLI has been closely correlated with BEAM. These tickers have moved in lockstep 69% of the time. This A.I.-generated data suggests there is a high statistical probability that if DNLI jumps, then BEAM could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To DNLI
1D Price
Change %
DNLI100%
-1.03%
BEAM - DNLI
69%
Closely correlated
-3.76%
NTLA - DNLI
65%
Loosely correlated
-2.64%
JANX - DNLI
59%
Loosely correlated
+1.64%
XNCR - DNLI
51%
Loosely correlated
-0.62%
LGND - DNLI
51%
Loosely correlated
-0.81%
More

RGNX and

Correlation & Price change

A.I.dvisor indicates that over the last year, RGNX has been loosely correlated with AXON. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if RGNX jumps, then AXON could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RGNX
1D Price
Change %
RGNX100%
-4.36%
AXON - RGNX
48%
Loosely correlated
+0.11%
DNLI - RGNX
44%
Loosely correlated
-1.03%
BEAM - RGNX
42%
Loosely correlated
-3.76%
SANA - RGNX
40%
Loosely correlated
-0.88%
XNCR - RGNX
40%
Loosely correlated
-0.62%
More